Long noncoding RNA TM1P3 is involved in osteoarthritis by mediating chondrocyte extracellular matrix degradation

Area of Science:

• Biochemistry
• Molecular Biology
• Cell Biology

Background:

• Osteoarthritis (OA) is a prevalent degenerative joint disease causing significant physical disability.
• Noncoding RNAs, including long noncoding RNAs (lncRNAs) and microRNAs (miRNAs), are implicated in chondrocyte extracellular matrix (ECM) degradation in OA.
• Understanding the roles of lncRNAs and miRNAs in OA pathogenesis is crucial for developing effective treatments.

Purpose of the Study:

• To investigate the impact of lncRNA-TM1P3 and miR-22 on chondrocyte ECM degradation in OA.
• To elucidate the underlying molecular mechanisms involved in this process.
• To identify potential therapeutic targets for OA.

Main Methods:

• Primary chondrocytes were cultured and treated with inflammatory stimuli (IL-1, TGF-β) or specific inhibitors to mimic OA conditions.
• Gene expression levels of miR-22, lncRNA-TM1P3, ALK1, MMP13, and SMAD signaling pathway components were quantified using real-time PCR and Western blot.
• Functional studies involved small interfering RNA (siRNA)-mediated knockdown of lncRNA-TM1P3 and manipulation of miR-22 levels using mimics or inhibitors.

Main Results:

• lncRNA-TM1P3 was significantly upregulated in OA, correlating with decreased miR-22 and increased MMP13 expression, leading to ECM degradation.
• Bioinformatics analysis suggested miR-22 is a target of both lncRNA-TM1P3 and MMP13.
• Knockdown of lncRNA-TM1P3 modulated ALK1 and SMAD signaling, impacting ECM degradation and MMP13 expression.

Conclusions:

• The lncRNA-TM1P3/miR-22/TGF-β signaling/MMP13 pathway is a critical regulator of chondrocyte ECM degradation in OA.
• This pathway represents a potential therapeutic target for novel OA treatments.
• Further research into this axis could lead to innovative strategies for managing osteoarthritis.